Behrenbruch Christian's Form 4 filing
Telix Pharmaceuticals Ltd (TLX) · filed May 6, 2026
- Accession no.
- 0001628280-26-031608
- Filed
- May 6, 2026
- Trade date
- Apr 28-29, 2026
- Filing delay
- 8 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $996.7K. It was filed 8 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Behrenbruch ChristianCIK 0002037713 | Director, Officer (MD & Group CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | Ordinary Shares | PPurchaseAcquired | +34,500 | $14.48 | +$499,560 | 20,709,500 | Indirect | |
| Apr 29, 2026 | Ordinary Shares | PPurchaseAcquired | +33,435 | $14.87 | +$497,178.45 | 20,742,935 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.